Login Register Cart 0
Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Mesenchymal Stem Cell Transplantation For Hepatitis B Virus-Related Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis

Author(s): Fang Cheng*, Zhong Huang, Wei Wei and Zhi Li

Volume 18, Issue 6, 2023

Published on: 13 January, 2023

Page: [834 - 842] Pages: 9

DOI: 10.2174/1574888X18666221214123844

Price: $65

conference banner
Abstract

Background: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a severe complication with a poor prognosis. Recently, mesenchymal stem cell (MSC)-based therapy for HBVACLF has shown considerable promise. Therefore, this systematic review and meta-analysis aimed to evaluate the efficacy and safety of MSC transplantation for patients with HBV-ACLF.

Methods: The PubMed, Cochrane Library, CNKI, and Embase databases were searched from their inception to March 2021 for reports on MSC therapy for HBV-ACLF. We used RevMan 5.3 to perform the systematic review and meta-analysis.

Results: Four studies were ultimately included. Compared with the control treatment, allogeneic MSC treatment resulted in a higher cumulative survival rate among ACLF patients (OR=2.27; 95% CI 1.35, 3.81; p=0.002). The umbilical cord-derived MSC (UC-MSC) group obtained a higher survival rate than the control group (OR = 2.33; 95% CI 1.17, 4.63; p=0.02). The group with multiple interval peripheral vein injections of MSCs obtained a higher survival rate than the control group (OR = 2.09; 95% CI 1.20, 3.67; p=0.01). None of the adverse events were MSC-related.

Conclusion: Our study indicates that MSC transplantation can significantly increase survival rates by improving liver function without severe adverse events. UC-MSCs harvested for allogeneic infusion via peripheral veins appear to provide superior treatment for patients.

« Previous Next »
Graphical Abstract

[1]
Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver (APASL): An update. Hepatol Int 2019; 13(4): 353-90.
[http://dx.doi.org/10.1007/s12072-019-09946-3] [PMID: 31172417]
[2]
Gu W, Xu B, Zheng X, et al. Acute-on-chronic liver failure in China: Rationale for developing a patient registry and baseline characteristics. Am J Epidemiol 2018; 187(9): 1829-39.
[http://dx.doi.org/10.1093/aje/kwy083] [PMID: 29762630]
[3]
Wu D, Zhang S, Xie Z, et al. Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure. J Clin Invest 2020; 130(4): 2069-80.
[http://dx.doi.org/10.1172/JCI130197] [PMID: 32175919]
[4]
Volarevic V, Nurkovic J, Arsenijevic N, Stojkovic M. Concise review: Therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis. Stem Cells 2014; 32(11): 2818-23.
[http://dx.doi.org/10.1002/stem.1818] [PMID: 25154380]
[5]
Lee KD, Kuo TKC, Whang-Peng J, et al. In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology 2004; 40(6): 1275-84.
[http://dx.doi.org/10.1002/hep.20469] [PMID: 15562440]
[6]
Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006; 24(4): 1030-41.
[http://dx.doi.org/10.1634/stemcells.2005-0319] [PMID: 16253981]
[7]
Shi M, Liu Z-W, Wang F-S. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol 2011; 164(1): 1-8.
[http://dx.doi.org/10.1111/j.1365-2249.2011.04327.x] [PMID: 21352202]
[8]
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6(7): e1000097.
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[9]
Higgins J, Green S. Cochrane handbook for systematic reviews for interventions. Cochrane Database Syst Rev 2011; 2011(2): S38.
[10]
Shi M, Zhang Z, Xu R, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med 2012; 1(10): 725-31.
[http://dx.doi.org/10.5966/sctm.2012-0034] [PMID: 23197664]
[11]
Li YH, Xu Y, Wu HM, Yang J, Yang LH, Yue-Meng W. Umbilical cord-derived mesenchymal stem cell transplantation in Hepatitis B virus related acute-on-chronic liver failure treated with plasma exchange and entecavir: A 24-month prospective study. Stem Cell Rev 2016; 12(6): 645-53.
[http://dx.doi.org/10.1007/s12015-016-9683-3] [PMID: 27687792]
[12]
Lin B, Chen J, Qiu W, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial. Hepatology 2017; 66(1): 209-19.
[http://dx.doi.org/10.1002/hep.29189] [PMID: 28370357]
[13]
Xu W, He H, Pan S, et al. Combination treatments of plasma exchange and umbilical cord-derived mesenchymal stem cell transplantation for patients with Hepatitis B virus-related acute-on-chronic liver failure: A clinical trial in China. Stem Cells Int 2019; 2019: 1-10.
[http://dx.doi.org/10.1155/2019/4130757] [PMID: 30863450]
[14]
Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy. Gut 2005; 54(11): 1604-9.
[http://dx.doi.org/10.1136/gut.2004.062208] [PMID: 15923670]
[15]
Garg H, Kumar A, Garg V, Sharma P, Sharma BC, Sarin SK. Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. Dig Liver Dis 2012; 44(2): 166-71.
[http://dx.doi.org/10.1016/j.dld.2011.08.029] [PMID: 21978580]
[16]
Mohamadnejad M, Vosough M, Moossavi S, et al. Intraportal infusion of bone marrow mononuclear or CD133+ cells in patients with decompensated cirrhosis: A double-blind randomized controlled trial. Stem Cells Transl Med 2016; 5(1): 87-94.
[http://dx.doi.org/10.5966/sctm.2015-0004] [PMID: 26659833]
[17]
Suk KT, Yoon JH, Kim MY, et al. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial. Hepatology 2016; 64(6): 2185-97.
[http://dx.doi.org/10.1002/hep.28693] [PMID: 27339398]
[18]
Wu YZ, Yang L, Zhai YF, Zhang HH, Huo LY. Therapeutic effect of autologous bone marrow mesenchymal stem cells on hepatic fibrosis, liver function, MELD score and 1-year survival rate in patients with decompensated hepatitis B. Chin J Tissue Eng Res 2017; 21(13): 2049-55.
[19]
Cao Z, Liu Y, Wang S, et al. The impact of HBV flare on the outcome of HBV‐related decompensated cirrhosis patients with bacterial infection. Liver Int 2019; 39(10): 1943-53.
[http://dx.doi.org/10.1111/liv.14176] [PMID: 31206235]
[20]
Peng L, Xie D, Lin BL, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: Short-term and long-term outcomes. Hepatology 2011; 54(3): 820-8.
[http://dx.doi.org/10.1002/hep.24434] [PMID: 21608000]
[21]
Peng L, Li H, Gu L, Peng XM, Huang YS, Gao ZL. Comparison of biological characteristics of marrow mesenchymal stem cells in hepatitis B patients and normal adults. World J Gastroenterol 2007; 13(11): 1743-6.
[http://dx.doi.org/10.3748/wjg.v13.i11.1743] [PMID: 17461481]
[22]
Juhas S, Martínek J, Ryska O, Dolezel R, Ryska M, Juhásová J. Autologous transplantation of mesenchymal stem cells into the portal vein of the miniature pig; a preliminary experiment for NOTES approach. Perspectives in Surgery 2019; 98(9): 350-5.
[http://dx.doi.org/10.33699/PIS.2019.98.9.350-355] [PMID: 31698910]
[23]
Sang JF, Shi XL, Han B, et al. Intraportal mesenchymal stem cell transplantation prevents acute liver failure through promoting cell proliferation and inhibiting apoptosis. Hepatobiliary Pancreat Dis Int 2016; 15(6): 602-11.
[http://dx.doi.org/10.1016/S1499-3872(16)60141-8] [PMID: 27919849]
[24]
Cao H, Yang J, Yu J, et al. Therapeutic potential of transplanted placental mesenchymal stem cells in treating Chinese miniature pigs with acute liver failure. BMC Med 2012; 10(1): 56.
[http://dx.doi.org/10.1186/1741-7015-10-56] [PMID: 22673529]
[25]
Xiang GA, Zhang GQ, Fang CH, Gao P, Chen KY. A preliminary study of the homing capacity of allograft mesenchymal stem cells to rat liver. J First Mil Med Univ 2005; 25(8): 994-7. [J].
[PMID: 16109558]
[26]
Kharaziha P, Hellström PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: A phase I–II clinical trial. Eur J Gastroenterol Hepatol 2009; 21(10): 1199-205.
[http://dx.doi.org/10.1097/MEG.0b013e32832a1f6c] [PMID: 19455046]
[27]
Terai S, Ishikawa T, Omori K, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 2006; 24(10): 2292-8.
[http://dx.doi.org/10.1634/stemcells.2005-0542] [PMID: 16778155]
[28]
Sun L, Fan X, Zhang L, et al. Bone mesenchymal stem cell transplantation via four routes for the treatment of acute liver failure in rats. Int J Mol Med 2014; 34(4): 987-96.
[http://dx.doi.org/10.3892/ijmm.2014.1890] [PMID: 25110277]
[29]
Piscaglia AC, Campanale M, Gasbarrini A, Gasbarrini G. Stem cell-based therapies for liver diseases: State of the art and new perspectives. Stem Cells Int 2010; 2010: 1-10.
[http://dx.doi.org/10.4061/2010/259461] [PMID: 21048845]
[30]
Zekri AR, Salama H, Medhat E, et al. The impact of repeated autologous infusion of haematopoietic stem cells in patients with liver insufficiency. Stem Cell Res Ther 2015; 6(1): 118.
[http://dx.doi.org/10.1186/s13287-015-0106-1]
[31]
Zhong YS, Lin N, Deng MH, Zhang FC, Tang ZF, Xu RY. Deficient proliferation of bone marrow-derived mesenchymal stem cells in patients with chronic hepatitis B viral infections and cirrhosis of the liver. Dig Dis Sci 2010; 55(2): 438-45.
[http://dx.doi.org/10.1007/s10620-009-0733-4] [PMID: 19242797]
[32]
Bongso A, Fong CY. The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton’s jelly of the human umbilical cord. Stem Cell Rev 2013; 9(2): 226-40.
[http://dx.doi.org/10.1007/s12015-012-9418-z] [PMID: 23233233]
[33]
Ding DC, Chang YH, Shyu WC, Lin SZ. Human umbilical cord mesenchymal stem cells: A new era for stem cell therapy. Cell Transplant 2015; 24(3): 339-47.
[http://dx.doi.org/10.3727/096368915X686841] [PMID: 25622293]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy